The ascendancy of Viagra and its influence on the medicinal landscape presents a complex question for investors. While the initial sales figures were astounding, the patent has ended, leading to a flood of generic alternatives that are eroding earnings. Moreover, the industry is facing challenges related to aging trends and shifting healthcare poli